🎉 M&A multiples are live!
Check it out!

Zentalis Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Zentalis Pharma and similar public comparables like Benevolent AI, Julphar, and Vivoryon Therapeutics.

Zentalis Pharma Overview

About Zentalis Pharma

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.


Founded

2014

HQ

United States of America
Employees

166

Website

zentalis.com

Financials

LTM Revenue $48.0M

LTM EBITDA -$191M

EV

-$244M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Zentalis Pharma Financials

Zentalis Pharma has a last 12-month revenue of $48.0M and a last 12-month EBITDA of -$191M.

In the most recent fiscal year, Zentalis Pharma achieved revenue of $67.4M and an EBITDA of -$186M.

Zentalis Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Zentalis Pharma valuation multiples based on analyst estimates

Zentalis Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $67.4M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$253M -$186M XXX XXX XXX
EBITDA Margin -Infinity% -276% XXX XXX XXX
Net Profit -$237M -$292M XXX XXX XXX
Net Margin -Infinity% -433% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Zentalis Pharma Stock Performance

As of April 15, 2025, Zentalis Pharma's stock price is $1.

Zentalis Pharma has current market cap of $87.6M, and EV of -$244M.

See Zentalis Pharma trading valuation data

Zentalis Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$244M $87.6M XXX XXX XXX XXX $-2.35

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Zentalis Pharma Valuation Multiples

As of April 15, 2025, Zentalis Pharma has market cap of $87.6M and EV of -$244M.

Zentalis Pharma's trades at -5.1x LTM EV/Revenue multiple, and 1.3x LTM EBITDA.

Analysts estimate Zentalis Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Zentalis Pharma and 10K+ public comps

Zentalis Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$244M XXX XXX XXX
EV/Revenue -3.6x XXX XXX XXX
EV/EBITDA 1.3x XXX XXX XXX
P/E -0.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Zentalis Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Zentalis Pharma Valuation Multiples

Zentalis Pharma's NTM/LTM revenue growth is -100%

Zentalis Pharma's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $1.5M for the same period.

Over next 12 months, Zentalis Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Zentalis Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Zentalis Pharma and other 10K+ public comps

Zentalis Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -276% XXX XXX XXX XXX
EBITDA Growth -26% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.4M XXX XXX XXX XXX
Opex per Employee $1.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 129% XXX XXX XXX XXX
R&D Expenses to Revenue 249% XXX XXX XXX XXX
Opex to Revenue 378% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Zentalis Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Small Molecules comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Zentalis Pharma M&A and Investment Activity

Zentalis Pharma acquired  XXX companies to date.

Last acquisition by Zentalis Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Zentalis Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Zentalis Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Zentalis Pharma

When was Zentalis Pharma founded? Zentalis Pharma was founded in 2014.
Where is Zentalis Pharma headquartered? Zentalis Pharma is headquartered in United States of America.
How many employees does Zentalis Pharma have? As of today, Zentalis Pharma has 166 employees.
Who is the CEO of Zentalis Pharma? Zentalis Pharma's CEO is Ms. Julie M. Eastland.
Is Zentalis Pharma publicy listed? Yes, Zentalis Pharma is a public company listed on NAS.
What is the stock symbol of Zentalis Pharma? Zentalis Pharma trades under ZNTL ticker.
When did Zentalis Pharma go public? Zentalis Pharma went public in 2020.
Who are competitors of Zentalis Pharma? Similar companies to Zentalis Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Zentalis Pharma? Zentalis Pharma's current market cap is $87.6M
What is the current revenue of Zentalis Pharma? Zentalis Pharma's last 12-month revenue is $48.0M.
What is the current EBITDA of Zentalis Pharma? Zentalis Pharma's last 12-month EBITDA is -$191M.
What is the current EV/Revenue multiple of Zentalis Pharma? Current revenue multiple of Zentalis Pharma is -5.1x.
What is the current EV/EBITDA multiple of Zentalis Pharma? Current EBITDA multiple of Zentalis Pharma is 1.3x.
Is Zentalis Pharma profitable? Yes, Zentalis Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.